3D Systems (DDD) stock price is $2.89, up 4.71% on the day, as of Oct 19, 2026. It has a market cap of $430.52Mn, and is classified in the 3D Printing industry (Industrials sector).
Enterprise Value
Margins
P/FCF
Key Stats
Market Cap430.52 Mn
P/E-7.85
P/S1.11
Div. Yield0.00
Total Debt (Qtr)91.18 Mn
Revenue Growth (1y) (Qtr)-0.27
Add ratio to table…
About
3D Systems Corporation provides comprehensive 3D printing and digital manufacturing solutions. The company designs manufactures and sells 3D printers for plastics and metals. It also develops proprietary materials software and related services. Its offerings serve two main industry verticals healthcare and industrial. The firm leverages more than three decades of experience to deliver end to end workflow solutions that help customers optimize designs transform production and…
3D Systems Corporation provides comprehensive 3D printing and digital manufacturing solutions. The company designs manufactures and sells 3D printers for plastics and metals. It also develops proprietary materials software and related services. Its offerings serve two main industry verticals healthcare and industrial. The firm leverages more than three decades of experience to deliver end to end workflow solutions that help customers optimize designs transform production and bring new products to market. The company invests in research and development to expand its technology platforms and improve material performance. It also pursues strategic partnerships that extend its reach into new geographic markets and application areas.
Revenue is generated primarily through the sale of 3D printers and associated print materials. The company also earns income from software licenses and subscription services that support printer operation and workflow management. Service revenues include maintenance training advanced manufacturing and application development support. Customers span healthcare providers medical device manufacturers dental labs aerospace firms automotive manufacturers and various industrial manufacturers. The firm benefits from recurring revenue streams as clients consume materials and use software services over the life of their equipment. Licensing arrangements and royalty streams from third party use of its patented technologies also contribute to overall income. Service contracts also provide predictable revenue over multi year periods.
The company operates through the following segments.
Healthcare Solutions focuses on delivering products and services for medical dental and regenerative medicine applications. The segment provides surgical planning tools implants instrumentation and anatomical models for hospitals and medical device companies. It also supplies clear aligner technology crowns bridges dentures and nightguards for dental professionals. Additionally the segment conducts pre commercial research in bioprinting aimed at creating transplantable tissues and organs.
Industrial Solutions serves aerospace defense transportation and general manufacturing markets. It offers high volume production capabilities for automotive consumer jewelry and other sectors where additive manufacturing enables mass customization and faster product development. The segment also supplies mission critical components for semiconductors oil and gas and other high reliability industries requiring precision and material performance.
3D Systems Corporation holds a notable position in the global additive manufacturing market. The company differentiates itself through a fully integrated ecosystem that combines hardware materials software and application engineering. This integration allows customers to move from design to production with reduced development cycles and lower risk. Competitors include other 3D printer manufacturers material suppliers and specialized software providers. However few rivals match the breadth of 3D Systems portfolio across both plastics and metals and its deep expertise in healthcare and industrial verticals. The firm’s long history strong intellectual property portfolio and worldwide service network provide competitive advantages that help it retain key accounts and win new business in emerging applications. The firm’s ability to provide customized application development and on demand manufacturing support further strengthens its market position. Several large corporations and numerous niche players compete for share in the rapidly evolving 3D printing industry.
3D Systems Corporation serves a diverse set of customers across healthcare and industrial sectors. In healthcare the company works with hospitals medical device manufacturers dental laboratories and research institutions focused on regenerative medicine. In industrial markets its clients include automotive manufacturers aerospace suppliers defense contractors jewelry makers and consumer goods producers. The firm also supplies services to government agencies energy companies and technology firms that adopt additive manufacturing for prototyping and production. Two healthcare customers accounted for a significant portion of revenue in recent years demonstrating the importance of key relationships in the segment. The company’s global sales force and network of channel partners enable it to serve customers in North America Europe Asia Pacific and other regions.
Sectors:Industrials·HealthcareSector rationaleThe company's primary revenue is generated from the design, manufacture, and sale of 3D printers (capital equipment) and associated materials for industrial applications such as aerospace, defense, and automotive. A substantial secondary business line exists in Healthcare Solutions, providing surgical planning tools, implants, and dental products specifically for hospitals and medical device companies.Industries:3D Printing3D PrintingPrimaryThe company designs, manufactures, and sells 3D printers for plastics and metals, as well as the associated print materials and software. Its core revenue is generated through the sale of these additive-manufacturing systems and recurring consumable materials.Medical DevicesMedical DevicesSecondaryThe company provides surgical planning tools, implants, and instrumentation for hospitals and medical device companies through its Healthcare Solutions segment.DentalDentalSecondaryThe company supplies clear aligner technology, crowns, bridges, dentures, and nightguards specifically for dental professionals and dental labs.Classified using BQ-MICSCIK: 0000910638
Bull & bear
Investment Thesis
▲ Bull case
The company’s refreshed product portfolio spanning direct metal printing systems and five major polymer platforms positions it to capture renewed demand as the additive manufacturing industry emerges from a multi year trough driven by macroeconomic and geopolitical headwinds. Management highlighted that sustained R&D investments during the downturn now enable the launch of new products that no competitor can match in breadth or performance. This advantage is especially pronounced in the three prioritized growth markets Aerospace & Defense Med Tech and Dental where the technology delivers unmatched quality precision reproducibility and regulatory compliance. As a result the firm expects to see continued double digit year over year growth in printer and material sales across these segments.
The denture printing solution NextDent 300 has achieved rapid adoption following U.S. regulatory approval and secured EU Phase IIa approval two months ahead of schedule expanding the addressable market to more than 60,000,000 edentulous patients roughly one third of the global opportunity. Early adopters such as ROE Dental Laboratory have already expanded capacity tripling output for high precision multi material monolithic dentures while reporting high production efficiency dentist acceptance and patient satisfaction. Management anticipates a solid order backlog entering Q2 FY26 and is raising internal production targets for the second half of the year to meet rising demand. This platform is projected to become a major contributor to revenue and profitability for many years ahead.
In Aerospace & Defense the firm is leveraging its unique dual approach to metal part production offering both direct metal printing and high precision SLA printed patterns for investment casting which together enable customers to work with exotic materials such as titanium zirconium nickel based alloys and copper nickel alloys critical for propulsion satellites and unmanned systems. The company has announced an expansion of its Littleton Colorado facility adding 80,000 square feet of manufacturing space with a grand opening slated for late summer to support rising demand for high end difficult metal components. Management expects over 20% year over year growth in this market translating to approximately 35,000,000 of revenue in FY26 driven by space naval and aero propulsion applications as well as growing use in precision munitions and unmanned aerial vehicles. This expansion should enhance capacity productivity and material flexibility as the 3D printed metal market continues to expand.
The company’s Healthcare segment surpassed Industrial Solutions as the larger revenue driver in Q1 FY26 with a 21% year over year increase fueled by strong performance in both Med Tech and Dental where material sales aligner sales and prosthetic materials are gaining traction. Management noted that the predictable nature of non optional high impact procedures such as orthopedic implants and spinal surgeries provides a stable demand base that is less susceptible to discretionary spending cuts. Continued investment in reducing response time for surgical guides to a couple of days enables participation in trauma cases expanding the total addressable market for printed implants. Together these factors suggest the Healthcare business can sustain double digit growth and improve margins as operating leverage kicks in with higher volumes.
The company’s refreshed product portfolio spanning direct metal printing systems and five major polymer platforms positions it to capture renewed demand as the additive manufacturing industry emerges from a multi year trough driven by macroeconomic and geopolitical headwinds. Management highlighted that sustained R&D investments during the downturn now enable the launch of new products that no competitor can match in breadth or performance. This advantage is especially pronounced in the three prioritized growth markets Aerospace & Defense Med Tech and Dental where the technology delivers unmatched quality precision reproducibility and regulatory compliance. As a result the firm expects to see continued double digit year over year growth in printer and material sales across these segments.
The denture printing solution NextDent 300 has achieved rapid adoption following U.S. regulatory approval and secured EU Phase IIa approval two months ahead of schedule expanding the addressable market to more than 60,000,000 edentulous patients roughly one third of the global opportunity. Early adopters such as ROE Dental Laboratory have already expanded capacity tripling output for high precision multi material monolithic dentures while reporting high production efficiency dentist acceptance and patient satisfaction. Management anticipates a solid order backlog entering Q2 FY26 and is raising internal production targets for the second half of the year to meet rising demand. This platform is projected to become a major contributor to revenue and profitability for many years ahead.
In Aerospace & Defense the firm is leveraging its unique dual approach to metal part production offering both direct metal printing and high precision SLA printed patterns for investment casting which together enable customers to work with exotic materials such as titanium zirconium nickel based alloys and copper nickel alloys critical for propulsion satellites and unmanned systems. The company has announced an expansion of its Littleton Colorado facility adding 80,000 square feet of manufacturing space with a grand opening slated for late summer to support rising demand for high end difficult metal components. Management expects over 20% year over year growth in this market translating to approximately 35,000,000 of revenue in FY26 driven by space naval and aero propulsion applications as well as growing use in precision munitions and unmanned aerial vehicles. This expansion should enhance capacity productivity and material flexibility as the 3D printed metal market continues to expand.
The company’s Healthcare segment surpassed Industrial Solutions as the larger revenue driver in Q1 FY26 with a 21% year over year increase fueled by strong performance in both Med Tech and Dental where material sales aligner sales and prosthetic materials are gaining traction. Management noted that the predictable nature of non optional high impact procedures such as orthopedic implants and spinal surgeries provides a stable demand base that is less susceptible to discretionary spending cuts. Continued investment in reducing response time for surgical guides to a couple of days enables participation in trauma cases expanding the total addressable market for printed implants. Together these factors suggest the Healthcare business can sustain double digit growth and improve margins as operating leverage kicks in with higher volumes.
The firm’s growth remains heavily concentrated in a limited number of key customers and end markets making performance vulnerable to any disruption in their operations or spending plans as illustrated by the temporary disruption at a major medical device customer that offset gains in printer sales during Q1 FY26. Management acknowledged that the rebound in demand from this customer is expected but did not provide visibility on the duration or likelihood of similar events recurring. This reliance creates upside risk to forecasts if additional customers experience supply chain or internal operational issues especially in regions affected by geopolitical tensions. Consequently any slowdown in these anchor accounts could disproportionately affect overall revenue growth.
Seasonality in the Healthcare business introduces a predictable headwind in the second quarter as patients tend to defer optional procedures such as teeth straightening or elective surgeries when they anticipate vacation periods leading to a sequential dip in revenue that management described as a little bit more of a seasonal dip for us because of the size of our Healthcare business. While the company expects to return to growth in the second half the timing of this dip could compress quarterly earnings and affect investor sentiment especially if macroeconomic conditions exacerbate discretionary spending cuts. The guidance for Q2 FY26 already reflects an adjusted EBITDA loss range of 2,000,000 to 4,000,000 indicating that the seasonal impact is not fully offset by cost savings or product mix improvements. Investors should monitor whether the seasonal pattern intensifies in future quarters as the Healthcare mix continues to expand.
Logistics challenges stemming from the ongoing conflict in the Middle East continue to disrupt the global flow of printers parts and materials increasing lead times and costs for both the company and its customers despite management’s comment that the issue is just a logistical nightmare rather than a demand driver. The firm noted that it has some customers in the region and that the conflict has screwed up logistics around the world which could erode margins if higher freight expenses or expedited shipping become necessary to meet delivery commitments. Persistent supply chain constraints could also limit the ability to scale production in the newly expanded Littleton facility delaying the realization of expected capacity utilization and revenue growth from Aerospace & Defense orders. If these disruptions persist they could force the company to allocate additional working capital to buffer inventory and absorb higher inbound logistics costs.
The company carries a debt schedule with 3,900,000 due in the Q4 FY26 and the remaining 92,000,000 maturing in 2030 which creates refinancing risk especially if cash flow generation remains volatile and the firm fails to achieve its target of break even adjusted EBITDA for the full year. While the balance sheet shows 86,500,000 in total cash including 85,100,000 in cash and cash equivalents the reliance on cash reserves to service debt could limit flexibility for strategic investments or unexpected downturns. Management’s expectation of stable operating expenses through the remainder of the year assumes continued success of cost reduction initiatives but any slowdown in those savings or unexpected inflationary pressures could push operating costs higher than anticipated. Should operating expenses rise unexpectedly the path to annual profitability could be delayed increasing pressure on the stock valuation.
The firm’s growth remains heavily concentrated in a limited number of key customers and end markets making performance vulnerable to any disruption in their operations or spending plans as illustrated by the temporary disruption at a major medical device customer that offset gains in printer sales during Q1 FY26. Management acknowledged that the rebound in demand from this customer is expected but did not provide visibility on the duration or likelihood of similar events recurring. This reliance creates upside risk to forecasts if additional customers experience supply chain or internal operational issues especially in regions affected by geopolitical tensions. Consequently any slowdown in these anchor accounts could disproportionately affect overall revenue growth.
Seasonality in the Healthcare business introduces a predictable headwind in the second quarter as patients tend to defer optional procedures such as teeth straightening or elective surgeries when they anticipate vacation periods leading to a sequential dip in revenue that management described as a little bit more of a seasonal dip for us because of the size of our Healthcare business. While the company expects to return to growth in the second half the timing of this dip could compress quarterly earnings and affect investor sentiment especially if macroeconomic conditions exacerbate discretionary spending cuts. The guidance for Q2 FY26 already reflects an adjusted EBITDA loss range of 2,000,000 to 4,000,000 indicating that the seasonal impact is not fully offset by cost savings or product mix improvements. Investors should monitor whether the seasonal pattern intensifies in future quarters as the Healthcare mix continues to expand.
Logistics challenges stemming from the ongoing conflict in the Middle East continue to disrupt the global flow of printers parts and materials increasing lead times and costs for both the company and its customers despite management’s comment that the issue is just a logistical nightmare rather than a demand driver. The firm noted that it has some customers in the region and that the conflict has screwed up logistics around the world which could erode margins if higher freight expenses or expedited shipping become necessary to meet delivery commitments. Persistent supply chain constraints could also limit the ability to scale production in the newly expanded Littleton facility delaying the realization of expected capacity utilization and revenue growth from Aerospace & Defense orders. If these disruptions persist they could force the company to allocate additional working capital to buffer inventory and absorb higher inbound logistics costs.
The company carries a debt schedule with 3,900,000 due in the Q4 FY26 and the remaining 92,000,000 maturing in 2030 which creates refinancing risk especially if cash flow generation remains volatile and the firm fails to achieve its target of break even adjusted EBITDA for the full year. While the balance sheet shows 86,500,000 in total cash including 85,100,000 in cash and cash equivalents the reliance on cash reserves to service debt could limit flexibility for strategic investments or unexpected downturns. Management’s expectation of stable operating expenses through the remainder of the year assumes continued success of cost reduction initiatives but any slowdown in those savings or unexpected inflationary pressures could push operating costs higher than anticipated. Should operating expenses rise unexpectedly the path to annual profitability could be delayed increasing pressure on the stock valuation.